Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Nov;32(11):2077-2081.
doi: 10.1002/oby.24126. Epub 2024 Aug 22.

GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea

Cliona O'Donnell  1   2 , Odhrán Ryan  3   4 , Andrew E Hogan  5 , Desmond Killick  3 , Shane Crilly  6 , Jonathan D Dodd  6 , David J Murphy  2   6 , Silke Ryan  1   2 , Donal O'Shea  2   3   4
Affiliations
Randomized Controlled Trial

GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea

Cliona O'Donnell et al. Obesity (Silver Spring). 2024 Nov.

Abstract

Objective: Glucagon-like peptide-1 (GLP-1) analogues are currently the most widely used pharmacotherapies for weight loss. Their primary mechanism of action is attributed to reduction in energy intake. Data from murine studies also support an additional impact of those agents on energy homeostasis through upregulation of visceral adipose tissue (VAT) metabolic activity, but this remains uncertain in humans.

Methods: Here, we present data from a proof-of-concept study on 30 individuals with obstructive sleep apnea and obesity who were randomized to a GLP-1 therapy-based weight loss regimen, continuous positive airway pressure, or a combination of both for 24 weeks. At baseline and study completion, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) was performed to evaluate VAT metabolic activity, expressed as VAT target to background ratio.

Results: Treatment with GLP-1, but not with continuous positive airway pressure, was associated with a significant increase in VAT target to background ratio. There was a strong correlation between the increase in VAT metabolic activity and the degree of weight loss.

Conclusions: These data support the hypothesis that upregulation of VAT metabolic activity by GLP-1 contributes to its weight loss action in humans, and this subject warrants further detailed investigation.

PubMed Disclaimer

References

REFERENCES

    1. Drucker DJ. GLP‐1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.
    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205‐216.
    1. Wilding JPH, Batterham RL, Calanna S, et al. Once‐weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989‐1002.
    1. Lynch L, Hogan AE, Duquette D, et al. iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy. Cell Metab. 2016;24(3):510‐519.
    1. O'Donnell C, Crilly S, O'Mahony A, et al. Continuous positive airway pressure but not GLP1‐mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof‐of‐concept study. Ann Am Thorac Soc. 2024;21(3):464‐473.

Publication types

Substances

LinkOut - more resources